Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988920 · ClinicalTrials.gov registry record · Phase 4
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
A Phase 4 study of End Stage Renal Disease and Hyperphosphatemia, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 4
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT03988920: Completed Phase 4 study of End Stage Renal Disease and Hyperphosphatemia, sponsored by Ardelyx.
NCT03988920 is a Phase 4 study of End Stage Renal Disease and Hyperphosphatemia that has completed, run by Ardelyx. The registered enrollment target is 172 participants, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988920, a Phase 4 study of End Stage Renal Disease and Hyperphosphatemia, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP \>2.5 and ≤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis with hyperphosphatemia (\>4.5 mg/dL).
Primary Outcome
Proportion of patients with serum phosphorus between 2.5 and 4.5 mg/dL
Conditions Studied
Interventions
- DRUG Tenapanor
- DRUG Sevelamer Carbonate
Study Locations (1)
California
- Ardelyx Site #509 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2019-06-15 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 4 |
What the finished NCT03988920 record still lists
NCT03988920 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Tenapanor is the first listed.
NCT03988920 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03988920 about?
NCT03988920 is a clinical study titled "A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP". The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP \>2.5 and ≤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis with hyperphosphatemia (\>4.5 m...
What is the current status of trial NCT03988920?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 172 participants. The study started on 2019-06-15. Estimated completion is 2021-07-31.
What conditions does trial NCT03988920 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Hyperphosphatemia.
What interventions are being tested in trial NCT03988920?
The interventions under investigation include: Tenapanor (DRUG), Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT03988920?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03988920's enrollment target sits among peer trials
172 24th of 86 higher than 63 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI